Nov 2017: Diagnosed with Stage IV high-risk Neuroblastoma. Nov 2017–Apr 2019: Completed standard treatment; NED. Apr 2019–Apr 2021: Completed DFMO clinical trial. Apr 2022: Relapse. Apr 2022–Jun 2023: Completed relapse treatment; NED again. Jun 2023–Jun 2024: High-dose DFMO (compassionate use) clinical trial. Jun 2024: Second relapse. Jul 2025: NED again. Mar 2026: Relapse.
Wednesday, March 25, 2026
Friday, February 6, 2026
Monday, November 24, 2025
Friday, November 7, 2025
Thursday, July 31, 2025
Wednesday, June 4, 2025
Thursday, May 15, 2025
Monday, May 12, 2025
Tuesday, May 6, 2025
Tuesday, March 25, 2025
Wednesday, February 26, 2025
Tuesday, February 11, 2025
Tuesday, January 28, 2025
Wednesday, January 22, 2025
Monday, January 13, 2025
Friday, January 10, 2025
Monday, January 6, 2025
Saturday, December 14, 2024
Monday, December 9, 2024
Friday, November 29, 2024
Friday, November 8, 2024
Monday, November 4, 2024
Monday, October 28, 2024
Monday, October 21, 2024
Monday, October 7, 2024
Saturday, October 5, 2024
Thursday, October 3, 2024
Friday, September 27, 2024